7.55
-0.38 (-4.73%)
| Penutupan Terdahulu | 7.92 |
| Buka | 7.85 |
| Jumlah Dagangan | 1,893,788 |
| Purata Dagangan (3B) | 5,091,074 |
| Modal Pasaran | 1,590,026,240 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.43 |
| Harga / Jualan (P/S) | 2.40 |
| Harga / Buku (P/B) | 56.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -10.62% |
| Margin Operasi (TTM) | 14.59% |
| EPS Cair (TTM) | -0.260 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 56.90% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -25.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 42.90 M |
| Pulangan Atas Aset (ROA TTM) | 4.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | BioCryst Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.38 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.20% |
| % Dimiliki oleh Institusi | 87.44% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (HC Wainwright & Co., 324.12%) | Beli |
| Median | 21.50 (184.96%) | |
| Rendah | 9.00 (Barclays, 19.28%) | Pegang |
| Purata | 21.00 (178.33%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 7.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Dec 2025 | 32.00 (324.12%) | Beli | 7.59 |
| Citizens | 05 Nov 2025 | 25.00 (231.35%) | Beli | 7.17 |
| Barclays | 04 Nov 2025 | 9.00 (19.28%) | Pegang | 6.76 |
| Needham | 04 Nov 2025 | 18.00 (138.57%) | Beli | 6.76 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |